Clinical Trial Update: Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium [Phase 3]

View source ↗

Summary

A completed Phase III trial evaluating Bilhvax with praziquantel to prevent clinical recurrences of Schistosoma haematobium infection (urinary schistosomiasis).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schistosoma Haematobium Infection

Drugs mentioned

• Bilhvax
• Praziquantel (Praziquantel)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Urinary Schistosomiasis, Schistosoma Haematobium | Phase 3 | Status: COMPLETED